Pfizer’s COVID-19 Oral Antiviral Candidate 89% Effective in Phase 2/3 Study
The novel COVID-19 investigational oral antiviral treatment PAXLOVID™ (PF-07321332; ritonavir) by Pfizer, was found to reduce the risk of hospitalization
Read moreThe novel COVID-19 investigational oral antiviral treatment PAXLOVID™ (PF-07321332; ritonavir) by Pfizer, was found to reduce the risk of hospitalization
Read moreRhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read moreFrench pharmaceutical company Valneva has reported positive results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 in the Phase 3
Read moreInterim Analysis of Phase 3 Study shows Merck and Ridgeback’s investigational oral antiviral Molnupiravir has reduced the risk of hospitalization
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreCalypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read moreReal-world data has shown the Vaxzevria vaccine (formerly AZD1222), co-developed by AstraZeneca, the University of Oxford and its spin-out company,
Read moreThe University of Oxford has commenced a Phase I clinical trial of a novel HIV vaccine candidate with vaccinations underway
Read moreIQVIA™ has launched it’s Clinical Data Analytics Suite (CDAS), a new SaaS-based clinical data analytics platform that combines structured and
Read moreAleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a partnership to advance the early phase clinical development of Aleta’s
Read more